Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

11P Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions

(2020) Y. Nagamoto et al.   ANNALS OF ONCOLOGY

HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

(2019) Maral DerSarkissian et al.   Journal of the National Comprehensive Cancer Network

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

(2019) Alessandro Russo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

(2019) Wenfeng Fang et al.   BMC CANCER

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations

(2019) Jenn-Yu Wu et al.   Clinical Lung Cancer

1529PPhase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

(2019) T M Kim et al.   ANNALS OF ONCOLOGY

P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions

(2019) G. Riely et al.   Journal of Thoracic Oncology

OA07.03 Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan

(2019) H. Udagawa et al.   Journal of Thoracic Oncology

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

(2018) Jonathan W. Riess et al.   Journal of Thoracic Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

(2018) Robert Charles Doebele et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

(2018) Seonggyu Byeon et al.   Cancer Research and Treatment

1450POsimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer

(2018) B van Veggel et al.   ANNALS OF ONCOLOGY

Activity of the Hsp90 inhibitor Luminespib Among Non-Small Cell Lung Cancers Harboring EGFR Exon 20 Insertions

(2018) Z Piotrowska et al.   ANNALS OF ONCOLOGY

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

(2018) Andrés F. Cardona et al.   LUNG CANCER

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations

(2017) Yi-Cheng Shen et al.   LUNG CANCER

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

(2017) Hai-Yan Tu et al.   LUNG CANCER

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment

(2017) Vanita Noronha et al.   OncoTargets and Therapy

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

(2016) J L Kuiper et al.   BRITISH JOURNAL OF CANCER

59PD Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis

(2016) B. Han et al.   Journal of Thoracic Oncology

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations

(2016) Guoping Cheng et al.   OncoTargets and Therapy

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

(2016) Yue-Lun Zhang et al.   Oncotarget

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

(2015) Jarushka Naidoo et al.   CANCER

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer

(2011) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH